Mayne Pharma Group Launches Amiodarone 200mg Tablets in the US

Mayne Pharma Group Limited announced the launch of amiodarone tablets, 200mg in the United States. Amiodarone is a generic alternative to Cordarone® tablets, indicated for life-threatening recurrent ventricular arrhythmia. This launch complements the existing amiodarone product range that includes 100mg and 400mg dose strengths.

Mayne Pharma’s CEO, Mr Scott Richards, said “Amiodarone tablets are one of the first products to be manufactured at our new Greenville, North Carolina manufacturing facility which was recently completed. This new solid oral dose manufacturing facility quadruples the Company’s US manufacturing capacity to well over 1 billion doses and importantly introduces significant capacity to manufacture potent compounds and new capability to manufacture modified-release bead/pellet products.”

Mayne Pharma directly markets more than 55 products and has a growing pipeline of more than 30 generic and branded drug products targeting US markets with IQVIA sales greater than US$5 billion. According to IQVIA, US brand and generic sales of amiodarone tablets, 200mg, were approximately US$22 million for the 12 months ending 31 January 2018.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s